LEA LEIV
Known title: Chief Financial OfficerCIK: 0000939012
LEA LEIV's purchase track record
LEA LEIV has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/13/2022 | CRVS | $26K | -11.5% | +329.3% | +8.7% |
| 3/16/2022 | CRVS | $77K | -38.1% | -40.9% | -9.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CRVS | ▲ Buy | Open Market | 4,000 | $3K | 12/14/2022 | View on chart |
| CRVS | ▲ Buy | Open Market | 30,000 | $22K | 12/13/2022 | View on chart |
| CRVS | ▲ Buy | Open Market | 13,878 | $23K | 3/17/2022 | View on chart |
| CRVS | ▲ Buy | Open Market | 35,160 | $54K | 3/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Corvus Pharma Q2 2026 Earnings Call Transcript Released
Corvus Pharmaceuticals released the transcript of its Q2 2026 earnings call. The document offers details on the company’s recent financial results and guidance for the upcoming period. Investors can review the call to better understand the company’s performance and strategic priorities.
Corvus Pharma Q2 2026 Earnings Call Transcript Released. Corvus Pharmaceuticals released the transcript of its Q2 2026 earnings call. The document offers details on the company’s recent financial results and guidance for the upcoming period. Investors can review the call to better understand the company’s performance and strategic priorities.